Rallybio
RLYB
66 hedge funds and large institutions have $42.4M invested in Rallybio in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 17 closing their positions.
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
6% more funds holding
Funds holding: 62 → 66 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.44% less ownership
Funds ownership: 9.98% → 9.54% (-0.44%)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
24% less capital invested
Capital invested by funds: $55.9M → $42.4M (-$13.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
+$6.16M |
| 2 |
Millennium Management
New York
|
+$446K |
| 3 |
Goldman Sachs
New York
|
+$285K |
| 4 |
AC
Almitas Capital
Santa Monica,
California
|
+$171K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$160K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$760K |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
-$648K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$508K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$371K |
RLYB Hedge Fund Activity: Q2 2024 in Review
66 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rallybio (RLYB) for Q2 2024, worth a combined $42.4M — down 24% from $55.9M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RLYB positions and 17 closed out — a net gain of 4 holders — while 13 added to existing stakes and 17 trimmed.
The largest buyer was Johnson & Johnson, opening a new position worth an estimated $6.16M. The largest seller was BlackRock, cutting an estimated $2.3M.
- 66 institutional investors held Rallybio (RLYB) as of Q2 2024, up from 62 in Q1 2024.
- Funds reported $42.4M of Rallybio stock for Q2 2024, down 24% quarter-over-quarter.
- 21 funds opened new Rallybio positions in Q2 2024 and 17 closed out, a net change of +4 holders.
- The largest Rallybio buyer in Q2 2024 was Johnson & Johnson, an estimated $6.16M added.
- The largest Rallybio seller in Q2 2024 was BlackRock, an estimated $2.3M sold.
Based on aggregated 13F filings for Q2 2024.